VitalCare Announces National Launch of Diabetes Treatment Centers: National Launch of FDA Approved iCAT Therapy Begins

VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets: VDTI), a Nevada Corporation, today announced the national launch for opening licensed diabetes treatment centers utilizing the micro-dose intravenous insulin pump technology together with proprietary algorithms and clinical protocols for providing Intercellular Activation Therapy (iCAT) for treating diabetes.

CARSON CITY, Nev. (Business Wire EON) April 22, 2008 -- VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets: VDTI), a Nevada Corporation, today announced the national launch for opening licensed diabetes treatment centers utilizing the micro-dose intravenous insulin pump technology together with proprietary algorithms and clinical protocols for providing Intercellular Activation Therapy (iCAT) for treating diabetes.

The iCAT treatment is currently being administered at several clinics in Arizona, Nevada, Utah, Florida, Texas and Puerto Rico, to those who suffer from Type 1 and Type 2 Diabetes, in addition to secondary complications of Type 2 Diabetes including hypertension, peripheral vascular disease, retinopathy, heart disease, peripheral neuropathy, kidney disease, and diabetic wounds.

Jimmy McDougald, CEO, stated, “Due to VitalCare’s clinical specialists’ succeeding in the treatment of Type 1, Type 2 and Secondary Complications of Type 2 Diabetes over the past two decades, our executive board has decided to open opportunities for licensing VitalCare Diabetes Treatment Centers affiliates with certified training for qualified healthcare providers, for the licensing and use of iCAT Therapy. It is VitalCare’s goal to make iCAT Therapy more accessible to the 21 million diabetics in North America. The VitalCare Diabetes Treatment Centers will either be company owned, joint ventured or licensed to select qualified medical professionals.”

About VitalCare Diabetes Treatment Centers, Inc.

VitalCare Diabetes Treatment Centers, Inc. is a publicly traded company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector. VitalCare will become the premier company bringing diabetes related medical devices and healthcare services direct to consumers, focusing on the emerging technology and treatment intervention for treating Type 1 and Type 2 Diabetes known as “Intercellular Activation Therapy (iCAT).”

Safe Harbor Statement: Forward-looking statements in this release with respect to VitalCare Diabetes Treatment Centers, Incorporated’s business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward- looking statements, including, but not limited to, certain delays beyond VitalCare Diabetes Treatment Centers, Incorporated’s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in VitalCare’s filings with the Securities and Exchange Commission.